Could a medication famous for improving erections also be associated with a longer life? A large U.S. study produced an attention-grabbing result: men with erectile dysfunction who received Viagra-class medications had a 25% lower rate of death from any cause than similar men who did not receive the drugs.
That sounds like excellent news for bedrooms, hearts, and anyone who enjoys a headline containing both “Viagra” and “lower death risk.” However, the findings need careful interpretation. The study found an association, not proof that erectile dysfunction drugs prevent death. The men were not all perfectly healthy, the researchers did not randomly assign treatment, and prescription records cannot reveal every difference between users and nonusers.
Even so, the research adds to growing evidence that phosphodiesterase type 5 inhibitors, commonly called PDE5 inhibitors, may affect more than sexual performance. These medications act on blood vessels throughout the body, making their possible relationship with cardiovascular health scientifically plausibleand worthy of much better research.
What Did the 25% Lower Death Risk Study Find?
The widely reported finding came from a retrospective observational study published in The Journal of Sexual Medicine. Researchers analyzed U.S. medical and pharmacy claims collected between 2006 and 2020 and linked them with mortality information from the National Death Index.
The analysis compared 23,816 men with erectile dysfunction who filled at least one prescription for a PDE5 inhibitor with 48,682 matched men who had erectile dysfunction but no recorded prescription for one of these drugs. The medications included sildenafil, tadalafil, vardenafil, and avanafilthe active ingredients found in products such as Viagra, Cialis, Levitra, and Stendra.
After matching the groups and adjusting for factors such as age, smoking, diabetes, high blood pressure, cholesterol disorders, coronary artery disease, and cardiovascular medications, researchers reported several notable associations:
- A 25% lower incidence of death from any cause among PDE5 inhibitor users.
- A 39% lower incidence of cardiovascular death.
- A 13% lower incidence of major adverse cardiovascular events.
- Lower rates of heart failure, unstable angina, and coronary revascularization.
The average follow-up lasted approximately three years, although follow-up periods differed between the treated and untreated groups. Researchers also observed that men with the greatest recorded medication exposure appeared to have the lowest rates of major cardiovascular events and death. That pattern resembles a dose-response relationship, but it does not mean that taking extra pills is beneficialor safe. The study measured tablets dispensed, not tablets actually swallowed, and it did not establish an ideal dose for heart protection.
Were These Really “Healthy Men”?
The phrase “healthy men” makes a tidy headline, but it oversimplifies the study population. Every participant had been diagnosed with erectile dysfunction, and many had cardiovascular risk factors such as diabetes, hypertension, high cholesterol, obesity, or a history of smoking. Some participants also had established coronary artery disease.
The study generally focused on men who had not recently experienced a major adverse cardiovascular event. That is not the same as assembling thousands of men with flawless arteries, perfect blood pressure, and a refrigerator stocked entirely with kale.
A more precise summary would be: Among a large group of U.S. men with erectile dysfunction, including many with cardiovascular risk factors, recorded use of PDE5 inhibitors was associated with lower cardiovascular-event and mortality rates.
This distinction matters because erectile dysfunction itself can be an early sign of vascular disease. The arteries supplying the penis are relatively small, so impaired blood flow may become noticeable there before narrowed arteries produce obvious heart symptoms. Current cardiovascular guidance increasingly treats vascular erectile dysfunction as a reason to evaluate blood pressure, cholesterol, blood sugar, smoking, weight, exercise habits, and overall heart risk.
How Viagra and Other PDE5 Inhibitors Work
During sexual stimulation, the body releases nitric oxide in penile tissue. Nitric oxide encourages production of cyclic guanosine monophosphate, or cGMP, a chemical messenger that relaxes smooth muscle and allows more blood to enter the penis.
An enzyme called phosphodiesterase type 5 breaks down cGMP. PDE5 inhibitors temporarily block that enzyme, allowing the blood-vessel-relaxing signal to last longer. They do not automatically produce an erection, manufacture sexual desire, or turn an awkward date into a romantic comedy. Sexual stimulation is still required.
Common PDE5 Inhibitors
- Sildenafil: Commonly sold as Viagra or a generic; usually taken as needed.
- Tadalafil: Sold as Cialis or a generic; available as an as-needed or once-daily treatment and typically lasts longer.
- Vardenafil: An as-needed medication with effects broadly similar to sildenafil.
- Avanafil: A newer, relatively fast-acting option for some patients.
The medications differ in how quickly they begin working, how long their effects last, how food affects absorption, and how they interact with other drugs. Choosing one should involve a licensed healthcare professional rather than a friend who refers to himself as a “supplement expert” because he owns a blender.
Why Might ED Drugs Be Connected to Better Heart Outcomes?
PDE5 is present in blood vessels beyond the penis. By preserving cGMP activity, PDE5 inhibitors can promote vasodilation and modestly lower blood pressure. Researchers have proposed several mechanisms that could potentially support cardiovascular health.
Improved Endothelial Function
The endothelium is the inner lining of blood vessels. Healthy endothelial cells help arteries expand, regulate inflammation, and maintain appropriate blood flow. Diabetes, smoking, high blood pressure, and atherosclerosis can impair this function. Some experimental and small clinical studies suggest PDE5 inhibition may improve nitric-oxide signaling and endothelial responsiveness.
Reduced Strain on the Heart
By dilating blood vessels, PDE5 inhibitors may reduce resistance against which the heart pumps. Certain drugs in this class are already approved for pulmonary arterial hypertension, a condition involving abnormally high pressure in the blood vessels of the lungs. That does not prove that ordinary erectile dysfunction doses prevent heart attacks, but it demonstrates that PDE5 inhibitors have meaningful cardiovascular effects.
Possible Effects on Inflammation and Arterial Stiffness
Researchers have also explored possible effects involving arterial stiffness, platelet activity, inflammation, heart-muscle remodeling, and protection during reduced blood flow. Much of this evidence comes from laboratory research, specialized patient groups, or observational studies. The mechanisms are promising hypotheses, not permission to prescribe Viagra as a multivitamin.
Association Is Not the Same as Causation
The most important word in this story is associated. Researchers observed that PDE5 inhibitor users died less often during the study period. They did not prove that the drugs caused the reduction.
Observational studies can adjust for recorded differences, but they cannot eliminate every hidden variable. Men who seek treatment for erectile dysfunction may be more engaged with healthcare, more physically active, more likely to have a partner, more willing to exercise, or more consistent about taking blood-pressure and cholesterol medications.
Conversely, physicians may avoid prescribing PDE5 inhibitors to men who are extremely frail, have unstable cardiovascular disease, use nitrates, or are not healthy enough for sexual activity. This can create a “healthy user” or prescribing bias: the group receiving the medication may have been healthier in ways that insurance data could not fully capture.
Researchers also lacked reliable information about sexual frequency, exercise, nonprescription drug use, diet, relationship status, medications obtained outside an insurance plan, and whether dispensed tablets were actually taken. The study was supported by a Sanofi grant, and the published paper disclosed relevant relationships involving researchers and participating organizations. Funding does not invalidate a result, but it belongs in a complete evaluation of the evidence.
A 2024 systematic review and meta-analysis also found that long-term PDE5 inhibitor use was associated with lower cardiovascular-event and mortality risks. However, much of the available evidence remained observational. The American College of Cardiology’s summary of the Princeton IV consensus similarly described PDE5 inhibitors as generally safe for appropriate cardiac patients and possibly cardioprotective, while emphasizing that prospective randomized trials are needed before causation can be claimed.
Should Healthy Men Take Viagra to Live Longer?
No. PDE5 inhibitors are not approved as anti-aging drugs or general cardiovascular-prevention medications. A man without erectile dysfunction should not begin taking sildenafil or tadalafil merely because an observational study reported lower mortality among users.
There is no established heart-protection dose for otherwise healthy men, no randomized trial proving that recreational use extends life, and no guarantee that the statistical association applies to an individual. Using more medication than prescribed may increase the risks of low blood pressure, headache, dizziness, visual symptoms, drug interactions, and prolonged erection without adding any benefit.
The practical message is not “everyone should take Viagra.” It is that erectile dysfunction deserves proper medical attention, cardiovascular risk factors should be evaluated, and appropriately prescribed PDE5 inhibitors may be safer for many men with stable cardiovascular disease than people once assumed.
Important Safety Rules for Viagra and Other ED Drugs
Never Combine PDE5 Inhibitors With Nitrates
Sildenafil, tadalafil, vardenafil, and avanafil can dangerously intensify the blood-pressure-lowering effects of nitrates. Nitrate medications include nitroglycerin, isosorbide mononitrate, and isosorbide dinitrate. Recreational “poppers” containing amyl or butyl nitrite are also unsafe with PDE5 inhibitors.
Current cardiovascular guidance generally recommends separating nitrates from short-acting PDE5 inhibitors by at least 24 hours and from tadalafil by at least 48 hours. Patients should never stop prescribed nitrate therapy on their own simply to use an ED medication. That conversation belongs with the prescribing clinician.
Discuss Heart Disease and Exercise Tolerance
Sexual activity temporarily increases heart rate and physical workload. Men with unstable angina, uncontrolled high blood pressure, severe heart failure, a recent untreated heart attack, or high-risk rhythm disorders may need cardiac evaluation before resuming sexual activity or using ED medication.
Review Other Medications
PDE5 inhibitors can interact with alpha-blockers, some blood-pressure medicines, certain antifungal drugs, some antibiotics, HIV medications, and riociguat. Kidney or liver disease may also require a lower starting dose.
Know the Warning Signs
Common side effects include headache, facial flushing, nasal congestion, indigestion, dizziness, back pain, muscle aches, and temporary visual changes. Seek urgent medical attention for an erection lasting longer than four hours, sudden vision loss, sudden hearing loss, fainting, or chest pain during sexual activity. Tell emergency clinicians when the most recent dose was taken so they can avoid giving an unsafe nitrate.
Beware of “Natural Viagra” and Mystery Enhancement Products
Products promoted as herbal, all-natural, instant, or prescription-free sexual enhancers can be riskier than legitimate prescriptions. The U.S. Food and Drug Administration has repeatedly found undeclared sildenafil, tadalafil, and other active drugs in supplements, honey products, capsules, and performance formulas.
Hidden ingredients make safe dosing nearly impossible. A consumer may unknowingly combine an undeclared PDE5 inhibitor with nitroglycerin or another interacting medication. Buying prescription treatment through a legitimate healthcare professional and licensed pharmacy may feel less adventurous than purchasing “Thunder Stallion Maximum Night Honey” from a pop-up advertisement, but boring can be wonderfully compatible with staying alive.
What Men Should Do When Erectile Dysfunction Appears
Occasional erection difficulty can happen because of stress, fatigue, alcohol, anxiety, or relationship concerns. Persistent ED, however, warrants evaluation rather than silent experimentation with random pills.
A healthcare professional may review blood pressure, cholesterol, blood sugar, testosterone when appropriate, medications, smoking, sleep, mental health, and cardiovascular symptoms. Treatment can include lifestyle changes, counseling, adjustment of contributing medications, prescription PDE5 inhibitors, vacuum devices, injections, or other therapies.
Exercise, weight management, a heart-healthy diet, smoking cessation, adequate sleep, and control of diabetes and hypertension can improve both cardiovascular and erectile health. The penis and the heart are not identical organs, but they are enthusiastic members of the same blood-vessel network. When circulation improves, both may appreciate the renovation.
Experiences Behind the Headline: What This Research Can Mean in Real Life
The following scenarios are educational composites rather than reports about identifiable patients. They illustrate common experiences discussed in clinical guidance and should not replace personal medical care.
Experience 1: The Man Who Thought ED Was “Just Getting Older”
Consider a 52-year-old office manager who notices that erections have become less reliable. He assumes age is the entire explanation and orders an enhancement supplement from an online advertisement. The product promises results “within minutes,” which is usually marketing language for “please do not ask too many questions.”
After discussing the problem with his primary care clinician, he learns that his blood pressure is high and laboratory tests show elevated cholesterol and blood sugar. His erectile dysfunction was not proof of coronary disease, but it became the reason those risk factors were discovered. He begins exercising, improves his diet, receives appropriate treatment, stops using the mystery supplement, and is prescribed sildenafil after his medication list is reviewed.
The most valuable outcome is not merely a better erection. The ED conversation opens a door to cardiovascular prevention that might otherwise have remained closed for years.
Experience 2: The Man With a Nitroglycerin Prescription
Now imagine a 64-year-old man with stable coronary artery disease. He rarely uses his nitroglycerin but still carries it. Embarrassed to discuss ED, he considers taking a pill offered by a friend.
Instead, he calls his cardiologist. The physician reviews his exercise tolerance, current symptoms, heart history, and whether nitrates remain medically necessary. Because PDE5 inhibitors and nitrates can cause a dangerous drop in blood pressure when combined, the decision requires more than a casual “it should probably be fine.” His care team may revise his angina treatment, approve an ED drug under clear instructions, or recommend a non-PDE5 option.
This experience demonstrates why prescription review is not bureaucratic decoration. The same medication that is safe for one man may be hazardous for another because of a single drug interaction.
Experience 3: The Man Who Reads “25% Lower Risk” as a Guarantee
A healthy 38-year-old sees the mortality headline and wonders whether daily tadalafil might function as inexpensive longevity insurance. He has no ED and no medical indication for the drug. He reasons that if some is associated with better outcomes, more must be bettera principle that also explains many regrettable buffet decisions.
A clinician would point out that the study did not randomly give PDE5 inhibitors to healthy men to test whether they lived longer. The users may have differed from nonusers in healthcare engagement, physical activity, sexual activity, relationships, income, medication adherence, and underlying illness. The apparent dose-response pattern was based on dispensed tablets, not a controlled heart-protection regimen.
For this man, the evidence supports conventional cardiovascular prevention: do not smoke, exercise regularly, maintain a healthy weight, control blood pressure and cholesterol, sleep adequately, and seek care for symptoms. Taking an unnecessary prescription drug would add risk without a proven benefit.
The Shared Lesson
These experiences highlight the most useful interpretation of the research. ED treatment should be individualized, erectile dysfunction can provide an opportunity to examine cardiovascular health, and PDE5 inhibitors may have broader vascular effects worth studying. None of that converts Viagra into an over-the-counter life-extension supplement.
Conclusion
The reported 25% lower death risk is scientifically intriguing but easy to overstate. In a large observational study, men with erectile dysfunction who filled prescriptions for PDE5 inhibitors experienced lower rates of all-cause death, cardiovascular death, and major cardiovascular events than matched nonusers.
The results are consistent with plausible effects on blood vessels and with other observational research. They also fit modern guidance recognizing erectile dysfunction as a potential marker of cardiovascular risk. Nevertheless, the study could not prove that Viagra, Cialis, or related medications caused men to live longer.
For men who have ED and are medically suitable candidates, PDE5 inhibitors remain effective first-line treatments with a well-understood safety profile. For men hoping to prevent heart disease or extend life, the prescription remains less glamorous but better proven: exercise, avoid tobacco, manage blood pressure, control cholesterol and diabetes, maintain a healthy weight, and obtain routine medical care.
Medical note: This article is for general education and is not a diagnosis or treatment recommendation. Do not begin, stop, combine, or change the dose of an erectile dysfunction or cardiovascular medication without guidance from a qualified healthcare professional.
